Gerold Meinhardt
Vice President, Head & Team Leads - Global Early Oncology Daiichi Sankyo
Gerold Meinhardt, MD, PhD joined Daiichi Sankyo in June 2020. As of July 14, 2025, he is Vice President; Head Early Oncology Team Leads.
Prior to that, he was Vice President, Global Team Lead, responsible for the development of trastuzumab deruxtecan (DS-8201, ENHERTU), the company’s lead ADC (co-developed with AstraZeneca), approved for different indications in multiple countries worldwide.
Seminars
Thursday 11th June 2026
Exploring the Success of Dxd ADC Platform in Optimizing Clinical Efficacy Through Plasma-Stable Linker-Payload Technology & Optimized DAR
4:00 pm
- Analyzing the design innovations of the DXd ADC platform, specifically the plasma-stable linker-payload to understand its role in enhancing tumor selectivity
- Discussing translational and clinical outcomes of this platform in achieving efficacy in multiple tumor types
- Demonstrating bystander antitumor effect and its enhanced ability in tumor killing
Tuesday 9th June 2026
Analyzing Current Trends With Antibody Formats, Payloads, Linkers & Conjugation Technologies to Explore Future Areas of Innovation
9:30 am
- Evaluating innovations in antibody formats and novel conjugates to bolster the success of tumor targeting
- Examining advances in payloads and linkers to improve potency and stability
- Investigating emerging conjugation technologies for efficient manufacturing of ADCs
